<DOC>
	<DOC>NCT02742779</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of single and multiple orally ascending doses of GDC-0310 administered in healthy participants as 4 parts including Part 1- a single dose (SD) part using a powder-in-capsule (PIC) formulation, Part 2- a multiple dose (MD) part using a PIC formulation, Part 3- a SD part using a solution formulation, and Part 4- a MD part using a solution formulation. Effects of food on pharmacokinetics (PK) will also be explored.</brief_summary>
	<brief_title>A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Female participants of nonchildbearing potential must meet the criteria defined in the protocol Body mass index within the range of 18.0 to 30.0 kilograms per meter square (kg/m^2), inclusive, and a minimum weight of 50.0 kg Have a clinically significant medical condition (e.g., hypertension; diabetes; impaired cardiac, renal or hepatic function; hyperthyroidism or hypothyroidism; neurological disorder; pain condition; hematologic disorder; psychiatric disorders requiring chronic medication) including any medical condition requiring treatment with medication (other than study drugs and medications specifically allowed by this protocol) during participation in the study Evidence of any hepatic impairment including any abnormal levels (i.e., greater than [&gt;] 1 × the upper limit of normal) of alkaline phosphatase, gamma glutamyl transpeptidase, alanine transaminase, aspartate aminotransferase or bilirubin Evidence of clinically significant renal impairment defined as &gt;1.3 × upper limit of normal creatinine History or presence of alcoholism or alcohol or substance abuse (not including nicotine or caffeine) within the previous 2 years or routinely consume 2 or more alcoholcontaining beverages per day or more than 10 units of alcohol per week (1 unit =150 milliliter (mL) of wine, 360 mL of beer, or 45 mL of 40 percent (%) alcohol) Have a positive urine drug test at screening or checkin or any other point during the study Are habituated to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week) or have a history of chronic pain requiring opiate use Have used tobacco or nicotinecontaining products within 3 months before study drug administration Have clinically significant abnormal laboratory values as determined by the principal investigator Have used any prescription or overthecounter medication or supplement within 14 days or 5 times the elimination halflife (whichever is longer) before administration of study drug and until the end of their participation in the study History of seizures, including in first degree relatives History of heritable myopathy, weakness, or paralysis, including in first degree relatives indicative of familial periodic paralysis Current treatment with medications that are well known to prolong the QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>